Stage III uterine cancer extends outside the uterus, but remains confined to the pelvis. Stage IIIA cancers invade the lining of the pelvis or fallopian tubes or cancer cells can be found free in the pelvis. Stage IIIBcancer invades the vagina. Stage IIIC cancers invade the pelvic and/or para-aortic lymph nodes.
The following is a general overview of the treatment of stage III uterine cancer. Circumstances unique to your situation and prognostic factors of your cancer may ultimately influence how these general treatment principles are applied. The information on this Web site is intended to help educate you about your treatment options and to facilitate a mutual or shared decision-making process with your treating cancer physician.
Optimal treatment of patients with stage III uterine cancer often requires more than one therapeutic approach. Thus, it is important for patients to be treated at a medical center that can offer multi-modality treatment involving gynecologic oncologists and radiation oncologists. Survival following treatment of stage III uterine cancer is influenced by the extent of spread of the cancer and the ability of the surgeon to remove all visible cancer.
The standard treatment for stage III uterine cancer is a total abdominal hysterectomy (removal of the uterus) and bilateral salpingo-oophorectomy (removal of the fallopian tubes and ovaries) with or without removal of the pelvic and para-aortic lymph nodes. The surgeon will attempt to remove as much cancer as possible without causing major side effects. Unfortunately, some women with stage III uterine cancer cannot have all the cancer removed, especially when the cancer extends to the wall of the pelvis, other patients with stage III cancer will have microscopic cancer cells that have spread outside the uterus and therefore were not removed by surgery. These cells can cause relapses that follow treatment with surgery alone, therefore some patients may benefit from additional adjuvant treatment to decrease the risk of cancer recurrence.
To learn more about surgery, go to Surgery for Uterine Cancer.
Adjuvant therapy is the delivery of cancer treatment following local treatment with surgery and may include chemotherapy, radiation therapy, hormonal therapy, and/or biologic therapy. The decision about the need for adjuvant therapy is influenced by the extent of the cancer and the grade of the cancer. The grade of the cancer refers to how abnormal the cancer cells appear.
The optimal approach to adjuvant therapy for Stage III uterine cancer remains uncertain. Women are most often treated with radiation therapy and/or chemotherapy.1 A Phase III clinical trial (described below) reported that adjuvant chemotherapy resulted in better survival than radiation therapy among women with Stage III or IV uterine cancer, but another study found that the two treatments were similarly effective. The combination of chemotherapy and radiation therapy may be more effective than either treatment alone, but information about combined treatment remains limited.
Radiation therapy: Unlike chemotherapy, radiation therapy is considered a local treatment. Cancer cells can only be killed where the radiation is delivered to the body. If cancer exists outside the radiation field, the cancer cells are not destroyed by the radiation. Women who are candidates for adjuvant radiation therapy may be treated with external beam radiation therapy and/or vaginal brachytherapy. External beam radiation therapy (EBRT) is given via machines called linear accelerators, which produce high-energy external radiation beams that penetrate the tissues and deliver the radiation dose deep into the areas where the cancer resides. Brachytherapy treatment involves the placement of a radioactive isotope into the vagina in order to treat the “vaginal cuff” region. The vaginal cuff is the part of the vagina that was closest to the uterus; it is a common site of uterine cancer recurrence. Radiation therapy may be used alone or in combination with chemotherapy.
Chemotherapy: Chemotherapy is a systemic therapy, meaning that it can kill cancer cells throughout the body. The first Phase III clinical trial to report a benefit of adjuvant chemotherapy in women with Stage III or IV endometrial cancer was a study known as GOG 122. The study compared chemotherapy with doxorubicin and cisplatin to whole abdominal radiation. The results suggested a benefit of chemotherapy: 55% of women treated with chemotherapy were predicted to be alive at five years, compared with 42% of women treated with radiation therapy. Women treated with chemotherapy also, however, tended to experience more severe side effects: 17% of women treated with chemotherapy discontinued treatment as a result of toxicity, compared with 3% of women treated with radiation therapy.2
Chemotherapy and radiation therapy were also compared in a study conducted in Italy. In this study, overall and progression-free survival were similar in patients treated with chemotherapy and patients treated with radiation therapy.3 The reasons for the different results between this study and GOG 122 remain uncertain, but may involve differences in the patient populations studied or the specific treatment regimens used.
Some research suggests that the combination of chemotherapy and radiation therapy may increase effectiveness. A study conducted in Europe among women with high-risk Stage I, II, IIIA, or IIIC endometrial cancer reported that the combination of radiation therapy and chemotherapy resulted in better progression-free survival than radiation therapy alone.4 Full results from this study have not yet been published.
Taken as a whole, previous studies suggest that adjuvant radiation therapy and/or chemotherapy benefit many women with Stage III endometrial cancer. The specific treatment regimen that is chosen often varies by the characteristics of the cancer.
Radiation Therapy as Primary treatment
Patients who are inoperable at diagnosis can be treated with a combination of brachytherapy and external-beam radiation therapy. For more information, go to Radiation Therapy for Uterine Cancer.
Strategies to Improve Treatment
The progress that has been made in the treatment of stage III uterine cancer has resulted from improved doctor and patient participation in clinical studies. Future progress in the treatment of stage III uterine cancer will result from continued participation in appropriate studies. Currently, there are several areas of active exploration aimed at improving the treatment of recurrent uterine cancer.
Supportive Care: Supportive care refers to treatments designed to prevent and control the side effects of cancer and its treatment. Side effects not only cause patients discomfort, but also may prevent the optimal delivery of therapy at its planned dose and schedule. In order to achieve optimal outcomes from treatment and improve quality of life, it is imperative that side effects resulting from cancer and its treatment are appropriately managed. For more information, go to Managing Side Effects.
Adjuvant Hormonal Therapy: Progestational agents have long been used in the treatment of advanced or recurrent uterine cancer because some cancer cells respond to treatment. Well-differentiated cancers respond better to progestational agents than undifferentiated cancers. Clinical trials are ongoing to evaluate hormonal therapy administered alone or in combination with chemotherapy, surgery and/or radiation therapy.
1 Miller DS, Fleming G, Randall ME. Chemo- and radiotherapy in adjuvant management of optimally debulked endometrial cancer. Journal of the National Comprehensive Cancer Network. 2009;7:535-541.
2 Randall ME, Filiaci VL, Muss H et al. Randomized phase III trial of whole-abdominal irradiation versus doxorubicin and cisplatin chemotherapy in advanced endometrial carcinoma: A Gynecologic Oncology Group study. Journal of Clinical Oncology. 2006;24:36-44.
3 Maggi R, Lissoni A, Spina F et al. Adjuvant chemotherapy vs radiotherapy in high-risk endometrial carcinoma: results of a randomized trial. British Journal of Cancer. 2006;95:266-271.
4 Hogberg T, Rosenberg P, Kristensen G et al. A randomized phase-III study on adjuvant treatment with radiation (RT) ± chemotherapy (CT) in early-stage high-risk endometrial cancer (NSGO-EC-9501/EORTC 55991). Presented at the 2007 annual meeting of the American Society of Clinical Oncology. Abstract 5503.